Aspen Neuroscience and Bambusa Therapeutics each target $134 million IPOs

Aspen Neuroscience, a cell‑therapy company focused on Parkinson's disease, and Bambusa Therapeutics, a bispecific biotech, have filed SEC documents outlining plans for initial public offerings.

Both firms aim to raise roughly $134 million. Aspen proposes to sell 9.4 million shares at $15‑$17 each, which could net about $134.5 million, with potential additional proceeds if underwriters purchase extra shares.

Aspen intends to allocate about $8 million of the proceeds to continue its phase 1/2a trial of its autologous therapy sasineprocel, and reserve $110 million for a future phase 3 program. Bambusa's use of funds was not detailed in the filing.

The filings mark the companies' first public disclosure of pricing expectations after earlier indications they were considering a listing.